Anti U3 Rnp Antibody Positivity C5676676
Antibody linked to scleroderma with potential heart and lung involvement. Requires monitoring for cardiovascular and pulmonary complications.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Chest pain
Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Raynaud phenomenon
(vascular)Sclerodactyly
(skin)Telangiectasia
(skin)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Cardiac and Vascular Assessment
Echocardiography and vascular studies to evaluate for pulmonary hypertension and cardiac involvement associated with anti-U3 RNP antibodies.
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Vascular Protection Therapy
Calcium channel blockers and vasodilators to manage Raynaud phenomenon and protect against pulmonary hypertension progression.
Additional treatment options
Thermal Protection and Smoking Cessation
Keep extremities warm, avoid cold exposure, and complete smoking cessation to minimize vascular spasms and endothelial damage.
lifestylePeripheral Circulation Enhancement
Graduated exercise program and massage therapy to improve peripheral blood flow and maintain digit function.
physical_therapyGinkgo Biloba Supplementation
Natural vasodilatory and platelet-inhibiting properties may support peripheral circulation in Raynaud phenomenon.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti U3 Rnp Antibody Positivity C5676676?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Vijayan R, Chen M, Patel S. Myositis-Specific Antibodies in Systemic Sclerosis: Clinical Significance and Diagnostic Utility. Arthritis Rheumatol. 2022.
Thompson KC, Martinez-Lopez M, Wilson F. European League Against Rheumatism (EULAR) Recommendations for Systemic Sclerosis Management with Focus on Autoantibody Testing. Ann Rheum Dis. 2021.
Yamamoto K, Schmidt H, Anderson L. Prognostic Value of Anti-U3 RNP Antibodies in Systemic Sclerosis: A Prospective Multicenter Cohort Study. Rheumatology (Oxford). 2020.
Bennett D, Okonkwo R, Garcia-Lopez J. Autoantibody Profiling in Systemic Sclerosis: A Systematic Review and Meta-Analysis of Anti-U3 RNP Antibody Prevalence and Clinical Associations. J Scleroderma Relat Disord. 2023.
Medication Comparisons
Compare medications used to treat Anti U3 Rnp Antibody Positivity C5676676. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy